6.52

4.96% -0.34

Gyre Therapeutics Inc (GYRE)

Overview News Price History Why GYRE Down? Discussions Forecast

Gyre Therapeutics Inc stock is traded at $6.52, with a volume of 67,004. It is down -4.96% in the last 24 hours and up +9.58% over the past month. Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Previous Close:

$6.86

Open:

$6.88

24h Volume:

67,004

Relative Volume:

0.73

Market Cap:

$726.91M

Revenue:

$117.05M

Net Income/Loss:

$-3.71M

P/E Ratio:

-83.70

EPS:

-0.0779

Net Cash Flow:

$1.67M

1W Performance:

-11.17%

1M Performance:

+9.58%

6M Performance:

-11.89%

1Y Performance:

-16.52%

1-Day Range:

$6.50

$6.885

1-Week Range:

$6.50

$7.47

52-Week Range:

$5.44

$9.42

Gyre Therapeutics Inc Stock (GYRE) Company Profile

Name

Gyre Therapeutics Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

(858) 284-0115

Address

12730 HIGH BLUFF DRIVE, SAN DIEGO

Employee

618

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

GYRE's Discussions on Twitter

Compare GYRE vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GYRE Gyre Therapeutics Inc	6.52	726.91M	117.05M	-3.71M	1.67M	-0.0779
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-25	Initiated	Jefferies	Buy
Aug-26-25	Initiated	H.C. Wainwright	Buy
Mar-11-25	Initiated	Noble Capital Markets	Outperform
Apr-29-21	Resumed	Stephens	Overweight
Feb-10-21	Initiated	Piper Sandler	Overweight
May-21-20	Initiated	Raymond James	Outperform
Jan-04-19	Initiated	Oppenheimer	Outperform
Feb-12-18	Reiterated	B. Riley FBR, Inc.	Buy
Feb-09-18	Reiterated	Chardan Capital Markets	Buy
Dec-08-17	Initiated	B. Riley FBR, Inc.	Buy
Jun-12-17	Initiated	Chardan Capital Markets	Buy
Jun-06-17	Initiated	Ladenburg Thalmann	Buy
Jun-30-16	Initiated	Rodman & Renshaw	Buy

View All

Gyre Therapeutics Inc Stock (GYRE) Latest News

Jul 07, 2026

Gyre Therapeutics highlights pipeline progress as investors watch fibrosis focus - ad-hoc-news.de

Jul 07, 2026

Jul 03, 2026

GYREGyre Therapeutics Inc Options - Finviz

Jul 03, 2026

Jun 30, 2026

Form 4 Gyre Therapeutics Inc For: 30 June By Investing.com - Investing.com Nigeria

Jun 30, 2026

Gyre Therapeutics (GYRE) director awarded 40,000 stock options at $5.95 - Stock Titan

Jun 30, 2026

Director Dan Weng receives 40,000-share option grant at GYRE (NASDAQ: GYRE) - Stock Titan

Jun 30, 2026

GYRE SEC FilingsGyre Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Jun 30, 2026

US High Growth Tech Stocks to Watch - simplywall.st

Jun 30, 2026

Jun 29, 2026

Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026

GYRE THERAPEUTICS (GYRE): Kaskela Law LLC Announces Shareholder Investigation of Gyre Therapeutics and Encourages Long-Term GYRE Investors to Contact the Firm - ACCESS Newswire

Jun 29, 2026

Jun 28, 2026

Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Value-Defensive Index - marketscreener.com

Jun 28, 2026

Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Growth-Defensive Index - marketscreener.com

Jun 28, 2026

Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Defensive Index - marketscreener.com

Jun 28, 2026

Jun 27, 2026

Price to earnings forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView

Jun 27, 2026

Jun 26, 2026

Price to earnings forward of Gyre Therapeutics Inc – LS:A3EE5F - TradingView

Jun 26, 2026

Price to book forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView

Jun 26, 2026

Enterprise value to EBITDA forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView

Jun 26, 2026

Enterprise value to EBIT forward of Gyre Therapeutics Inc – TRADEGATE:L9S - TradingView

Jun 26, 2026

Price to earnings forward of Gyre Therapeutics Inc – TRADEGATE:L9S - TradingView

Jun 26, 2026